<2>Si-Bone Inc Form 4 Analysis: A Comprehensive Overview
<3>Introduction
<4>Si-Bone Inc, a leading medical device company, has recently filed a Form 4 with the Securities and Exchange Commission (SEC). This document provides valuable insights into the company’s executive compensation and insider trading activities. In this article, we will delve into the details of the Form 4 and analyze its implications for the company and its stakeholders.
<3>Background
<5>Si-Bone Inc is a medical device company that specializes in developing and marketing minimally invasive surgical solutions for patients with sacroiliac (SI) joint disorders. The company’s flagship product, iFuse, is a titanium implant designed to treat SI joint fusion. Si-Bone Inc has established itself as a leader in the orthopedic industry, with a strong presence in the United States and international markets.
<3>Form 4 Details
<6>The Form 4 filed by Si-Bone Inc provides information on the company’s executive compensation and insider trading activities. The document reveals that the company’s CEO, Jeffrey Dunn, sold 10,000 shares of common stock on March 10, 2024, at a price of $23.50 per share